Hospital for Special Surgery, New York, NY.
Spine (Phila Pa 1976). 2021 Apr 1;46(7):413-420. doi: 10.1097/BRS.0000000000003825.
Randomized, double-blinded, controlled trial.
To investigate the effectiveness of local intraoperative corticosteroids at decreasing the severity of swallowing difficulty following multilevel anterior cervical discectomy and fusion (ACDF).
Dysphagia is a common complication after ACDF, and while for most patients the symptoms are mild and transient, some patients can suffer from severe dysphagia resulting in significant postoperative morbidity. Previous studies investigating the local application of corticosteroids are limited.
This was a prospective, randomized, double-blinded, controlled trial of patients undergoing 2, 3, or 4 level ACDF for radiculopathy and/or myelopathy. Patients undergoing multilevel ACDF were randomized to receive local corticosteroid in the retropharyngeal space or placebo (no steroid). Dysphagia was assessed using validated outcomes including the Eating Assessment Tool-10 (Eat-10) and Swallowing Quality of Life (SWAL-QOL) Questionnaire both preoperatively and at 1 day (POD1), 2 days (POD2), and 1-month postoperatively.
One-hundred nine patients had a complete dataset available for analysis. Eat-10 scores were significantly lower in the Steroid group on POD2 (8 vs. 16, P = 0.03) and 1-month postoperatively (2 vs. 5, P = 0.03). A comparison of the individual SWAL-QOL subscale scores demonstrated that patients in the Steroid group had better scores than the Control group in various subscales at all postoperative time points. Significant differences were noted (always in favor of the Steroid group) in 40% of subscales on POD1, 60% of subscales on POD2, and 50% of subscales at 1-month postoperatively. The Control group never had a better SWAL-QOL subscale score at any time point postoperatively.
Local administration of corticosteroid after multilevel ACDF can decrease postoperative severity and symptomatology of dysphagia during the immediate postoperative period to 1-month postoperatively. The long-term effects of local steroid administration on fusion and other complications will need to be established in future studies.Level of Evidence: 1.
随机、双盲、对照试验。
研究术中局部应用皮质类固醇能否降低多节段前路颈椎间盘切除融合术(ACDF)后吞咽困难的严重程度。
吞咽困难是 ACDF 的常见并发症,虽然大多数患者的症状轻微且短暂,但有些患者可能会出现严重的吞咽困难,导致术后严重发病率。先前研究皮质类固醇局部应用的研究有限。
这是一项前瞻性、随机、双盲、对照试验,纳入因神经根病和/或颈椎病而行 2、3 或 4 节段 ACDF 的患者。接受多节段 ACDF 的患者随机分为接受咽后空间局部皮质类固醇或安慰剂(无类固醇)。使用经过验证的结果评估吞咽困难,包括术前和术后 1 天(POD1)、术后 2 天(POD2)和 1 个月时的饮食评估工具 10 分(Eat-10)和吞咽生活质量问卷(SWAL-QOL)。
109 例患者有完整数据集可供分析。POD2(8 分比 16 分,P=0.03)和术后 1 个月(2 分比 5 分,P=0.03)时,类固醇组的 Eat-10 评分明显更低。比较各个 SWAL-QOL 亚量表评分,在术后各个时间点,类固醇组患者的评分均优于对照组。在术后 1 天,40%的亚量表(总是有利于类固醇组)、术后 2 天,60%的亚量表和术后 1 个月,50%的亚量表有显著差异。在术后任何时间点,对照组的 SWAL-QOL 亚量表评分都没有更好。
多节段 ACDF 后局部应用皮质类固醇可在术后即刻至术后 1 个月减轻吞咽困难的严重程度和症状。局部类固醇给药对融合和其他并发症的长期影响需要在未来的研究中确定。
1 级。